entertainment -WSS

entertainment

author：entertainment 2025-09-28 10:00:19 - browse：1574

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

WSS

Ohioans vote in high

In venture capital firm's success, lessons for turning crisis into profit

HHS names first

New Medicare drug pricing powers could soon be upended in court

Zapping the brain for stroke rehab: Pivotal clinical trial begins

New England Journal of Medicine addresses racist history, slavery

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

Discs beat pads, tampons for heavy menstrual flow, new study shows

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Three issues to watch in global health in 2024

Virginia high school admissions case could be legal follow

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Duchenne breakthrough therapy leaves behind pioneering families

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

In age of alternative facts, a scholarly course on calling out crap

In venture capital firm's success, lessons for turning crisis into profit

entertainment

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Hospitals use virtual reality to design more inclusive rooms for kids

Former Georgia lieutenant governor says he received grand jury subpoena

DeSantis can now import cheaper drugs. But will Biden get credit?

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Judge rejects Trump's counterclaim against E. Jean Carroll

focus

focus

focus

hotspot